Our DFS result for treated stage I patients appears similar to the benefit obtained by a similar cohort published by Rodrigues et al (2010) in a retrospective review of Trastuzumab use in T1a,bN0 HER2+ breast cancer. Here, ERBB2 is linked to breast cancer.